RESOURCES | PLAYBOOK
HoT IP licence playbook
This document outlines the key matters that are included in a Heads of Terms (HoT) document for the licensing of Intellectual Property (IP) developed at a University to a non-spinout company. The HoT document is a preliminary agreement framework that sets out the principal terms for the future IP licensing arrangement. The HoT document does not cover all the legal clauses which would be included in the subsequent licence, but it is a useful guide for drafting to ensure all parties are clear on expectations around the key commercial issues.
HoTs for licensing of IP to a University spinout company is discussed in a separate Playbook.
Section 1 - Purpose
This Playbook aims to provide guidance to inventors and Technology Transfer Office staff (TTO) with whom inventors need to work closely to develop a licence agreement. Commercial organisations (or potential licensees) who have less experience of working with UK Universities may also find the description of common University licensing principles useful. The guide may also be used in conjunction with the 2023 USIT Guide, which, whilst focused on spin-out transactions, provides some market expectations that could also be useful for non-spinout licensing transactions. This Playbook is not exhaustive, providing summary guidance on the matters set out in the IMPACT-IP template.

HoTs provide early assurance to the parties at the key negotiation phase as they enable agreement on the most important commercial parameters of the (potential) licence deal, before having to spend time and money negotiating a full licence agreement. HoTs provisions generally do not have terms that are legally binding themselves. However, importantly, they do include particular elements (such as confidentiality, exclusivity and governing law) that the relevant parties optionally want to be, and expressly state as being, legally enforceable. If the parties reach agreement on the key commercial terms contained in the HoT, then most of the information is available to incorporate into the final phase of negotiation on the full IP licence agreement, often simplifying negotiation of this agreement.
Section 2 - IMPACT-IP HoTs
The IMPACT-IP HoTs template has been designed to cover the key commercial licensing terms only. More detailed agreements are available that can take longer to negotiate at the outset, but subsequently may reduce time spent negotiating the full agreement. As already identified, this guide provides the framework for the licence agreement but does not make recommendations on any of the potential commercial terms (e.g. royalty rates, other financial parameters) themselves, which are available elsewhere, including the USIT guides.
The HoTs include the key commercial terms of the deal covering: IP rights being licensed, the field, level of exclusivity, royalty rate(s), milestone payments, diligence milestones and sub-licensing rights, etc. However, the HoTs also include other key licence conditions important to the University, such as Restricted Sectors, sub-licensing conditions, institutional preserved licence rights, diligence obligations, summary liability and warranty expectations. Also, any important rights (such as any funders’ commercialisation consent requirements or former collaborators’ joint ownership involvement) carried forward from the original research activity that led to the IP to be licensed. Although most terms are not legally binding, it is unlikely that the key deal parameters, agreed in the HoTs, will change substantially, if at all, in the actual licence agreement. Therefore, it is important to consider these key terms very carefully.

The HoTs also consider the unique nature of Universities and their legal obligations:
- in the context of the charitable status of Universities and their obligation to safeguard IP to support the University and further its charitable purpose;
- to ensure the University complies with the terms of any third party research funder (e.g. medical research charities); and
- as a public body, to comply with subsidy control requirements.
As Universities are charities, they have limited scope to negotiate any warranties/indemnities and they therefore are required to adopt a cautious approach to risk. For example, Universities do not accept uncapped liabilities, as this is inconsistent with the spirit and intent of charity law.
Section 3 - Key Licence Terms
The following sections follow the structure of the HoT for Licence:
1. Grant of Licence
Grant of Licence: the use rights that are being granted under the University’s intellectual property (IP) and describes the key scope of the proposed licence, how and for what it can be used, and by whom.
An important aspect to consider is whether the licence is Exclusive or Non-Exclusive, as this will have knock-on implications for the remainder of the agreement. In general, an Exclusive Licence will have greater requirements for exploitation (on the Licensee) than a Non-Exclusive Licence, as the Company is getting greater access and control over the IP. Companies generally request an Exclusive Licence, as they tend to be targeting a significant commercial opportunity and seek to gain ‘exclusive’ protection in their key ‘market’ along with requiring assurance for securing essential private investment. An Exclusive Licence is generally preferred, as a non-exclusive licence would mean that third parties can be granted competing licence rights.
Licence Agreements can include single or multiple types of IP: patents, copyright, know-how. It is possible therefore for there to be multiple Exclusive Licences that may be further separated by Field, Territory or both.
The Company and TTO will need to consider carefully the use cases for the licensed IP, taking into account aspects such as freedom-to-operate, third party consents, and funder obligations, where applicable.
2. Intellectual Property
The IP to be licensed should be described clearly. In particular, registered rights such as patent applications and patents should be identified by application or publication number(s). The description of IP will govern the scope of IP rights that are on the table for ultimately being licensed to the Company.
It is important to be clear about the type(s) of IP under discussion at the earliest stages of negotiations since the terms of the agreement are likely to be heavily influenced by the form of IP that is being licensed.
Know-how is generally licensed non-exclusively. However, in some cases exclusivity can be granted, where:
- The Know-how is capable of being defined clearly and therefore documented. This enables the parties to understand what know-how is being licensed and allows the TTO to conduct appropriate due diligence ahead of licensing
- The academic concerned is comfortable that the Know-how does not become publishable information and receives advice on any consequences.
The template does not currently provide a section for detailed know-how, but this can be added to a schedule if it is important to identify this during HoT negotiations.
3. Field
The Field governs the sector or end-uses in which the IP can be used. Specifying the Field is essential to ensure that there is control over the appropriate use of the IP whilst giving the Company sufficient flexibility over product development and sales. Exclusive Licences can be granted to the Company but also to third parties in different Fields via separate licensing agreements. For example, a Licence to a therapeutic or diagnostic technology could be granted to the Company for veterinary purposes only, and to a different company for use solely in humans. However, as well as granting a licence for use of the IP in a specific Field, in line with policies of the University, it may also be necessary to prohibit the use of IP in other areas or fields that could cause reputational damage to the University such as tobacco, gambling and weapons. These are often referred to as Restricted Sectors and each University is likely to have its own policy.
It is often important to ensure that the description of the Field delineated for specific markets is not too broad, particularly for long-term licences or unique technologies. From the licensee perspective, the Field needs to be defined in a way that captures as clearly as possible the intended research and commercial applications. Depending on the circumstances, parties may need to consider competition law issues (for example, where a licensee is in a dominant position).
4. Territory
The Territory will govern where in the world the Company is entitled to use and commercialise products falling in scope of the licensed rights and preventing competitors from doing this, this can be either Worldwide or restricted to specific Territories. Companies tend to prefer the Territory to be as wide as possible, ie. Worldwide, but specific cases may involve other factors restricting the breadth of the Territories.
Some IP rights, such as patents are territorial, and this may need to be reflected in the HoTs. Also, it is important to pay attention to national security and export control matters as well as embargo / official sanction lists. Granting a Licence which is specific to certain Territories can also be useful where there are a number of companies operating in the same field who may have customer bases in different Territories. Granting a Licence in specific Territories can help to maximise market access as the IP is made available to a larger number of end users.
During some negotiations, a Company may insist that a Licence has worldwide coverage. This can be to ensure that they are free to implement the IP in any country in which they operate which should be reflected in their business plans.
5. Term
The Term is the agreed duration for which the license agreement is active and enforceable. The Term will start on the effective date of the full license agreement. Knowing how long the licence will last is important so that both the University and the Company know precisely how long their arrangement is supposed to last. This helps with planning, investments, and knowing when obligations might cease.
The Term could be perpetual for know-how, for the “life” of the patent itself or another specified duration. The licence could also include an initial term (e.g. 1 year) with renewal periods that commence automatically unless terminated in advance.
Where IP, particularly patents, are licensed alongside know-how, it is common to see language such as “X years from first sale of a licensed product or the life of the patents, whichever is longer”. This may give the licensor rights to royalties for a sensible period if the patents fall away for any reason but prevent the licensee from paying know-how only royalties for an unreasonably long period.
Other common ways to define Term are:
- Fixed Period: The duration of the agreement may last for a set number of years (e.g., "5 years from the Effective Date").
- Tied to an event: The licence could end at a specific event (e.g., "until the last relevant patent expires").
- Extendable: The agreement might have an initial Term with options to renew for additional periods if both parties agree (or if specific conditions are met).
6. Sub-Licensing
The University usually decides on whether it is able to grant sub-licensable rights and, if so, the degree of freedom provided to the spinout to enter into any Sub-Licensing Agreements. It is important to state whether or not University consent is going to be required for the Company to grant sub-licenses. Considerations may also include any funder obligations or limitations, such as a requirement to inform a funder or request permissions to sub-license outputs of funded research.
In general, the sub-licence terms are set to be no less onerous than those set out by the University in the main ‘Licence’. For example, as with the main licence, there will be restrictions on the entity taking a sub-licence, for example, not tobacco or pornography companies. This ensures the University remains protected against adverse risk generated through any actions of the sub-licensee.
The Company will need to consider if any sub-licence automatically terminates with the head-licence. This may seem appropriate but may impact the licensee’s ability to sub-license the IP rights, potentially reducing the potential benefit that could be realised through the transaction.
The Company will also need to consider the financial terms required for a sub-licence which, for instance, may be a pass-through Royalty Rate (discussed in Section 3.9.4) or a higher percentage compared to the head-licence agreement.
7. University Reserved Rights
The University needs to reserve certain rights in all its icence agreements and it is important to clarify these in the HOTs. These reservations are intended to balance the University's primary objective, as a research and teaching led organisation, to disseminate knowledge, with its ability to enter into appropriate commercialisation deals with external partners.
One crucial Reserved Right is the right of the University, its staff and its students, to be able to continue to use the licensed IP for non-commercial research and teaching purposes, despite the fact an exclusive licence is granted to the Company. In this case, we incorporate a reciprocal licence granted back for non-commercial research and teaching activities, including in collaboration with other third non-commercial parties. In addition, the University will insist on the ability to publish its research post-licensing, although short delays to publication to review for protectable IP or to remove any Compnay confidential information are usually acceptable, and will be important from the perspective of the Company. The Company may wish to restrict publication of exclusively licensed Know-how so as to retain its value to the Company.
8. Ethics Matters and Excluded Sectors
The University is obligated to ensure that all research and the subsequent commercialisation of the IP generated by the research, adheres to high standards of ethics, integrity, and responsibility. This includes compliance with all legal and professional frameworks and thorough ethical reviews of relevant research.
The Company will eventually be required to ensure any ongoing R&D, testing of or using Licenced Products on humans or animals including clinical trials, shall first obtain relevant ethical, regulatory approvals and CE marking. The Company will also need to commit to not using Licensed IPR and Licensed Products in activity relating to certain Restricted Sectors that are delineated by the University.
9. Financial Terms, Payments and Costs
The following sections describe common elements that are generally considered when determining the appropriate benefit structure for the licensing transaction. The overall structure varies across different deals, and it should be emphasised that some components are more suited to specific deals than others. The most appropriate fee structure is dependent on technology maturity, the market/ industry and stage of the IP/technology development lifecycle. The USIT Guide provides a comprehensive description of fee components that are particularly well suited to licensing of IP to Companies.
9.1 Upfront Payment
An upfront fee can be payable by a licensee in return for the University entering into the agreement. Any upfront payment would be dependent on a range of factors such as the technology's stage of development, market potential, risk, historic patent costs and comparable deals. In general, early-stage technologies are subject to smaller upfront payments (if any), with more value tied to future milestones and royalties. Payments also vary based on exclusivity, licence scope, and the type of company involved. Ultimately, an upfront payment is based on a negotiation aimed at balancing risk and reward for both parties.
9.2 Patent Costs
This sets out whether the Company will be required to reimburse all the patent or other IP costs incurred to protect and prosecute the IP rights going forward from the Effective Date. Typically, if the licence is exclusive the Licensee will be responsible for these ‘forward costs’ and some institutions also require partial or full reimbursement of historic patent costs. If there are multiple Licensees, then requiring them to share costs may be appropriate. In addition to meeting costs, the parties may wish to consider who should be responsible for taking the lead on any IP prosecution matters.
9.3 Annual Fees
Some licences use a simple fee charged annually for the Licence that is, in general, independent of royalties or minimum royalties. Annual Fees can be useful as a “basic” fee mechanism, especially for early-stage technologies and also as an incentive for the licensee to engage in the commercialisation of the IP. The fees may vary over the Term of the Licence and/or may have a fixed duration and can sometimes be useful to incentivise use by the Company of some or all of the IP package.
9.4 Royalties
Royalties are payments made by the Company to the University in return for the licensed use of the IP during the term of a Licence Agreement. Most typically, royalties will be set as a percentage of net sales (Net Sales Value) on products or services that make use of the licensed IP. However, a Royalty based on a fixed fee per unit sale can be appropriate in some circumstances. Royalty fees, therefore, are fundamentally variable and dependent on the level of activity.
Net Sales Value will be comprehensively and appropriately defined in the full licence agreement, but typically is the invoiced price less customary deductions such as shipping costs, packaging, returned items, tax and other payable duties. Differing Royalty Rates can be set for different product categories or Royalties can change over time during the term of the Licence, often linked to product income (referred to as Tiered Royalties)
Minimum Royalties can also be set. These are reasonable expectations of potential earned royalties that might be due every year (or other period). If the actual earned and reported royalties ( i.e. those payable on Net Sales) are less than the Minimum Royalty in the reporting period, then the Minimum Royalty amount will become due, as the terms require the greater of actual or the Minimum Royalty to be paid. Minimum Royalty amounts can change over the term of the licence, often they will increase on the basis that a Licensees’ sales are usually expected to increase over time as the product establishes a presence in the marketplace. This structure is used to incentivise Licensees to increase sales and the schedule of these annual levels set would be negotiated.
Guidance on ‘market’ royalty rates should be sought before in-depth discussions with the Company. The USIT Guides provide sector based recommended ranges for spinouts and other royalty rate databases exist for non-spinouts (e.g. Moodys, Royalty Rate, RoyaltyStat, KtMine, SEC’s Edgar database etc ). These can be useful, but every deal is likely to have a unique set of circumstances that the parties need to take into account in order to determine appropriate royalty rates
Royalty rates can vary substantially from sector to sector and are dependent on the specific application of the licensed technology. Over time, particular technologies or sectors can establish certain norms in licensing terms to have “industry standard royalty rates” but in early-stage technologies there will be less of an established market and business model, so royalty terms tend to be negotiated on a case-by-case basis.
9.5 Milestone Payments
Milestone Payments are time, developmental or success-based payments that are a reward for the increasing value of the technology being licensed. This helps the University to benefit from the success of the technology and is beneficial to the Company as Milestone Payments are only payable on success or increased value, i.e. when revenues or value is generated and not upfront when the risks are greater. Examples include milestone payments upon reaching key development stages e.g. initiation of a clinical study of a therapeutic, regulatory approval in key territories, or sales-based milestones (i.e. annual sales in excess of X in a monitoring period).
9.6 Net Receipts
Royalties on Net Receipts includes a percentage of payments from a sub-licensee, receipt of upfront fees, profit from R&D costs, milestone payments, share sales or issuance, monies awarded as a consequence of litigation or interest on loans. In these circumstances, a royalty based on a proportion of Net Receipts (of these payments) is reasonable given that the IP licence has provided these value generating opportunities.
The percentage of Net Receipts payable to the University can be fixed for the duration of the term of the Licence but may be reduced over time or over technology maturity levels (e.g. non-clinical, clinical, regulatory approval) as this represents the increase in the value of the technology and value inflection points for the Company. It is important to clarify whether royalties on product sales from sub-licensees fall under net receipts or royalty rate and to understand the different impacts this might have on earned royalties.
10. Commercialisation
The University will insist that Company’s undertake Diligent and Reasonable Efforts (DRE) to develop and commercially exploit the licensed technologies or products. In order to generate impact from research outputs, it is important to Universities that their Licensees are actively developing and commercialising the licensed IP. As DRE can be difficult to enforce due to the degree of subjectivity, it is typical to see Diligence or Development Milestones included in the licence agreement. These are clearly defined milestones that need to be reached by a given date, e.g. initiation of clinical studies, or product launch. The Milestones should be considered in light of University’s reasonable expectations of timelines and the Licensees development and commercialisation plans. Failure to achieve the milestones in the specified timescales can be linked to a right of termination or possibly a loss of exclusivity (with a remedy period).
11. Reporting and Audit Rights
The timing and content of development and royalty reports are usually included in the HoTs. In some cases, there may be obligations to report progress to external funders at regular intervals and so it may be necessary to include these provisions in a HoT to ensure that this is feasible for the Licensee. Universities may also have a requirement to obtain information for the purposes of reporting relating to The Research Excellence Framework (REF).
Regular reporting can be particularly important in licences that include Milestone Payments. Regular reporting ensures that project outcomes can be monitored to understand when milestone payments are due.
Payment schedules can also be included in a HoTs to outline when royalty payments will be distributed e.g. quarterly, annually etc. Audit Rights are insisted upon so that the University has the option to have an independent accountant ensure the payment reports and amount of any payments made are in accordance with the terms and conditions of the subsequent licence.
12. Assignment/Change of Control
Assignment and Change of Control provisions govern when either party may transfer their rights and obligations, and also what happens if the Company gets acquired or is subject to change of control.
Universities will insist that the Company is not able to assign the Licence Agreement to another entity without the University’s prior consent. Also, if the Company undergoes a Change of Control (to be defined in the Licence Agreement) without prior consent the University may look to terminate the Licence Agreement.
Without these terms, the licensed rights could pass automatically to an acquirer of the Licensee without the University’s permission. This could cause a potential reputational risk or a situation in which the rights are passed to a Company that may not be the most appropriate to commercialise the technology. Insisting on a right to give consent, often not to be unreasonably withheld, is a normal University position.
13. Warranties and Limits of Liability
13.1 Warranties
Warranties are fundamental promises each party makes in the agreement. In a Licence Agreement, it is crucial for the University to warrant that they hold the necessary rights and permissions to license the IP. Typically, the University will warrant that it is the registered applicant of the patent (or other IP) and that it has taken confirmatory assignments from its employees.
Universities are not in a position to give other warranties and will expressly exclude a range of potential risks such as the successful development of products based on the IP. This is because a Breach of Warranty is generally considered a material breach of the licence agreement and is inherently serious because it misrepresents the capabilities or conditions of the University. Explicit clarity and certainty are key to drafting this clause in the licence agreement. Universities may prefer to warrant such rights and permissions to the extent of “the best of their knowledge”, due to the IP generation / ownership chain being complicated within academia. The Universities also cannot warrant that the Licensees use of the technology will not infringe another entity’s (third party) IP.
13.2 Limits of Liability
Limits of Liability defines the limits of the responsibilities for each party and sets a cap on the level of loss or damages for which the University may be liable if anything goes wrong. The Company is in control of its future actions in terms of developing and using the licensed IP and the ultimate commercialisation into products and services. The Company therefore has the principal responsibility to manage and be responsible for risk generated during the process and the University cannot be expected to incur a liability as a result of the Company’s use of the licensed IP. The University will expect to be indemnified by the Company for any claims made against the University by a third party as a result of Company’s activity.
There may also be limitations on the scope of liabilities, for example, excluding certain kinds of damages or placing a monetary limit on the level of damages that can be claimed. The University will expect to cap the aggregate level of liabilities to a reasonably low level given its position as a charity. This is often set in line with internal guidance with little flexibility for variation.
14. Insurance
The University will require the Company to carry comprehensive general insurance and product liability cover; as a minimum, this should be at a level that reflects the Company’s, and therefore the University’s, potential liabilities under the licence agreement.
15. Governing Law & Jurisdiction
The licence agreement will set out the governing law, as well as the jurisdiction in which any dispute arising in connection with the licence agreement will be heard, e.g.,” law and courts of England and Wales”. This term sets out in advance which courts would have the necessary competence to resolve any such dispute. The governing law and jurisdiction generally correspond (though not always) to ensure that disputes are adjudicated under a consistent and expected legal framework.
16. Confidentiality
The parties are likely to want to ensure that the exchange of information in relation to the licence negotiation (and information around the University technology and Company’s commercial plans) remain confidential. It is highly likely that the parties will have a NDA in place already. The parties may be content that this existing NDA is suitable and sufficient, although this should be discussed and agreed.
The HoT template provides an option (option A) for the parties to confirm this by reference to the existing NDA. The NDA would need to be made part of the HoT as a legally binding agreement and so would at least need to incorporate a Governing Law and Jurisdiction section.
If there is no NDA in place, or the existing NDA is unlikely to be sufficient to cover subsequent negotiations then the template provides an optional confidentiality clause (Option B). This would cover future negotiations but parties should discuss whether this conflicts with any existing NDA or is suitably robust to cover disclosures. If this option is chosen then again, this would need to be a legally binding provision.
17. Exclusivity
The template HoT provides for the optional inclusion of an exclusivity period during which neither of the Parties may enter into any agreement, negotiations or discussions for the grant of commercial licences to the IP in the Field and the Territory with any third party.
Companies are generally keen on including an Exclusivity period so they know that the University will not negotiate licence terms with another party during this Exclusive period.
The University may grant a short exclusivity period, but there may be reasons for the University not to agree to this term. For example, the University may be in discussions with other potential licensees to secure the best deal for creating impact and income from the underlying IP assets.
Resources
Explore our ‘how-to’ guides and legal agreement resources to streamline spin-out company formation, help find investment and optimise licensing transactions.
PLAYBOOKS
How to guides explaining the ‘why’ and the ‘how’ of the commercial deal, ensuring an efficient process.
View PlaybooksTEMPLATES
A suite of lawyer-reviewed, legal Templates for everyone in the commercial deal to use.
View TemplatesCHECKLISTS
Useful Checklists to ensure that all critical elements are considered in the commercial deal.
View Checklist